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Abstract
Interferon-b is an established treatment for patients with multiple sclerosis (MS) but its mechanisms of action are not well
understood. Viral infections are a known trigger of MS relapses. Toll-like receptors (TLRs) are key components of the innate
immune system, which sense conserved structures of viruses and other pathogens. Effects of interferon-b on mRNA levels of
all known human TLRs (TLR1-10) and the TLR adaptor molecule MyD88 were analyzed in peripheral blood mononuclear cells
(PBMCs) of healthy donors by quantitative real-time PCR and by transcriptome analysis in PBMCs of 25 interferon-b-treated
patients with relapsing-remitting MS. Regulation of TLR protein expression by interferon-b was investigated by flow
cytometry of leukocyte subsets of healthy subjects and of untreated, interferon-b-, or glatiramer acetate-treated patients
with MS. Interferon-b specifically upregulated mRNA expression of TLR3, TLR7, and MyD88 and downregulated TLR9 mRNA
in PBMCs of healthy donors as well as in PBMCs of patients with MS. Plasmacytoid dendritic cells (pDCs) were identified as
the major cell type responding to interferon-b with increased expression of TLR7 and MyD88 protein. In line with this,
expression of TLR7 protein was increased in pDCs of interferon-b-treated, but not untreated or glatiramer acetate-treated
patients with MS. Interferon-b-induced upregulation of TLR7 in pDCs is of functional relevance since pre-treatment of
PBMCs with interferon-b resulted in a strongly increased production of interferon-a upon stimulation with the TLR7 agonist
loxoribine. Flow cytometry confirmed pDCs as the cellular source of interferon-a production induced by activation of TLR7.
Thus, upregulation of TLR7 in pDCs and a consequently increased activation of pDCs by TLR7 ligands represents a novel
immunoregulatory mechanism of interferon-b. We hypothesize that this mechanism could contribute to a reduction of
virus-triggered relapses in patients with MS.
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Introduction
Interferons were originally described as a family of antiviral
proteins, owing to their capacity to interfere with viral replication
[1]. Based on several pivotal clinical trials, interferon-b, a type I
interferon, was approved as the first disease-modifying therapy for
multiple sclerosis (MS), a chronic inflammatory CNS disease, in
the 1990ies [2–4]. While interferon-b consistently reduces relapse
rates by about one third and decreases disease activity as measured
by magnetic resonance imaging in patients with relapsing-
remitting MS (RRMS), the mechanisms of action underlying
these effects are not well understood [5].
Toll-like receptors (TLRs) are pattern-recognition receptors,
which recognize conserved structures of microbial pathogens,
referred to as pathogen-associated molecular patterns [6,7]. They
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are key components of the innate immune system whose activation
orchestrates inflammatory responses and primes antigen-specific
adaptive immunity. In humans, 10 functional TLRs (TLR1-10)
have been identified so far. All TLRs are transmembrane proteins
that can roughly be divided into cell surface-associated TLRs
(TLR1, TLR2, TLR4-6) primarily sensing microbial membrane
components, and TLRs located in intracellular vesicles (TLR3,
TLR7-9) detecting viral or bacterial nucleic acids [6]. Except for
TLR3, all TLRs recruit the Toll/interleukin-1 receptor (TIR)
domain-containing adaptor molecule myeloid differentiation
primary response gene 88 (MyD88) for activation of a complex
intracellular signaling cascade [6].
Here, we hypothesized that one mechanism of action of
interferon-b in MS may be related to regulation of TLRs. We
thus performed a comprehensive study on the impact of
interferon-b on mRNA expression levels of TLR1-10 and
MyD88 in peripheral blood mononuclear cells (PBMCs) of healthy
donors and of interferon-b-treated patients with RRMS. We
observed an upregulation of TLR3, TLR7, and MyD88 and a
downregulation of TLR9 by interferon-b in PBMCs of healthy
donors as well as in PBMCs of patients with RRMS. Plasmacytoid
dendritic cells (pDCs) were identified as the main cell type
upregulating TLR7 and MyD88 protein in response to interferon-
b and TLR7 was increased in pDCs of interferon-b-treated
patients with MS. As a functional consequence, upregulation of
TLR7 was accompanied by an enhanced production of interferon-
a upon TLR7 stimulation. These results suggest that upregulation
of the virus-detecting immune receptor TLR7 in pDCs and a
subsequently enhanced activation of pDCs by TLR7 ligands may
be a novel immunoregulatory mechanism of interferon-b in
patients with MS.
Materials and Methods
Ethics statement
The study was approved by the institutional review boards of
Charite´ - Universita¨tsmedizin Berlin (EA1/182/10) and Universi-
ta¨t Rostock (II HV 27/2003). Written informed consent was
obtained from all healthy donors and patients participating in the
study.
Cell separation, cell culture, and stimulation assays
Approximately 30 ml of peripheral venous blood were collected
from patients treated at the Department of Neurology or
NeuroCure Clinical Research Center, Charite´ - Universita¨tsme-
dizin Berlin, with a diagnosis of a clinically isolated syndrome
(CIS) suggestive of MS or early RRMS (disease duration #2
years), according to the McDonald 2005 criteria [8]. Samples were
processed within 1 hour and PBMCs were isolated by ficoll density
gradient centrifugation. PBMCs were frozen immediately by using
freezing medium containing 10% dimethyl sulfoxide and a
standard freezing container with isopropyl alcohol. Subsequently,
cells were thawed and used for flow cytometry analysis. PBMCs
from healthy donors were generated likewise and used directly
after isolation for in vitro stimulation assays. Freshly isolated
PBMCs from healthy donors were cultured in RPMI 1640
medium supplemented with 10% FCS and 1% penicillin/
streptomycin at a density of 26106 cells/ml in the absence or
presence of 10, 100, or 1000 U/ml interferon-b-1b (BetaferonH,
Bayer Pharma AG, Berlin, Germany) dissolved in NaCl solution
(5,4 mg/ml). For RNA extraction cells were harvested after 6, 24,
and 48 hours of treatment and for FACS analysis after 16 or
24 hours of treatment.
RNA isolation and cDNA synthesis
Total RNA was extracted from PBMCs using the RNeasy Mini
Kit (Qiagen, Hilden, Germany). Genomic DNA was eliminated by
on-column DNase digestion (RNase-Free DNase Set, Qiagen).
RNA concentrations were determined with a BioMateTM 3
spectrophotometer and analyzed by VISIONlite software
(Thermo Fisher Scientific, Waltham, USA). 1 mg of total RNA
of each sample was reverse transcribed into cDNA using Moloney
Murine Leukemia Virus Reverse Transcriptase (Promega, Madi-
son, USA) according to the manufacturer’s protocol.
Quantitative real-time polymerase chain reaction
Gene expression was analyzed by quantitative real-time
polymerase chain reaction (qRT-PCR) using SYBRH Green-based
RT2 qPCR Primer Assays (SABiosciences/Qiagen) for TLR1-10
and MyD88. Myxovirus-resistance protein (MX1) and hypoxan-
thine-guanine phosphoribosyltransferase (HPRT) served as posi-
tive control and housekeeping gene, respectively. qRT-PCR was
performed using a 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, USA). PCR reactions were performed in
duplicates, and results were expressed as the average of relative
gene expression normalized for HPRT mRNA expression for each
study subject and fold change of expression calculated by the
22DDCt method [9]. Set-up experiments confirmed that mRNA
expression levels of the housekeeping gene HPRT were not
modulated by interferon-b treatment (data not shown).
Flow cytometry
Cell surface phenotyping of PBMCs and intracellular expression
of TLR7 and MyD88 protein was measured by flow cytometry.
To detect pDCs (CD142CD123+CD303+) and monocytes
(CD14+), PBMCs were stained with anti-CD14 Pacific Blue
antibody (Ab) (clone M5E5, BioLegend, San Diego, USA), anti-
CD123 PerCP-Cy5.5 Ab (clone 6H6, eBioscience, San Diego,
USA), and anti-CD303 APC Ab (clone AC144, Miltenyi Biotec,
Bergisch Gladbach, Germany). To identify myeloid dendritic cells
(mDCs, CD142CD123lowCD1c+CD11chigh), PBMCs were
stained with anti-CD14 Pacific Blue Ab, anti-CD123 PerCP-
Cy5.5 Ab, anti-CD1c PE (clone L161, BioLegend), and anti-
CD11c APC Ab (clone 3.9, BioLegend). To mark CD19+ B cells,
CD4+, and CD8+ T cells, PBMCs were stained with anti-CD19
APC Ab (clone HIB19, eBioscience), anti-CD4 PerCP-Cy5.5 Ab
(clone RPA-T4, BD Biosciences, Heidelberg, Germany), and anti-
CD8 Pacific Blue Ab (clone RPA-T8, BD Biosciences). For
intracellular staining cells were fixed, permeabilized using the BD
Cytofix/CytopermTM Kit (BD Biosciences), and stained with anti-
TLR7 Alexa488 Ab (clone 66H3, Dendritics, Lyon, France) or
anti-MyD88 Alexa488 Ab (clone 4d6, Imgenex). An Alexa488-
conjugated isotype (Imgenex) was used as a negative control.
Fc receptors were blocked with FcR Blocking Reagent (Miltenyi
Biotec) before cell surface and intracellular staining. 56105 viable
cells (healthy donor samples) and 36105 cells (patient samples)
were acquired using a BD FACSCantoII cytometer (BD Biosci-
ences, San Jose, USA) and analyzed using FlowJo9 software (Tree
Star, Ashland, USA). All patient samples were coded and
examiners were blinded to the patients’ treatment status. Results
were expressed as mean fluorescence intensity (MFI) with the level
of expression calculated as delta (D) MFI=MFITLR7 or MyD88 –
MFIisotype.
Analysis of cytokine production upon TLR7 stimulation
PBMCs (26106 cells/ml) were cultured for 12 hours with or
without 1000 U/ml interferon-b, followed by stimulation with the
IFN-b Modulates TLRs in MS
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TLR7 ligand loxoribine (0,1 mM, InVivoGen) for an additional
6 hours. Supernatants were harvested and stored at 280uC.
Protein expression of interferon-a, tumor necrosis factor-a,
interferon-c-induced protein 10, macrophage inflammatory pro-
tein-1a, interleukin (IL) -6, IL-8, IL-10, IL-23, and IL-27 was
determined in cell culture supernatants by using the multianalyte
detection system FlowCytomixTM (eBioscience) according to the
manufacturer’s instructions. pDCs were analyzed for intracellular
interferon-a production by flow cytometry staining with an anti-
interferon-a FITC Ab (Miltenyi Biotec). Brefeldin A (5 mg/ml) was
added to PBMCs for the final 3 hours of stimulation.
Gene expression profiling with microarray analysis
Experimental details of the gene expression microarray analysis
were previously described [10]. Briefly, 25 Caucasian individuals
from a previously published cohort of patients treated with
interferon-b-1b [10,11] were included in this study (16 females, 9
males; mean age 39.6 years). They were diagnosed with RRMS
according to the McDonald 2001 criteria [12] and started on a
therapy with 250 mg interferon-b-1b administered subcutaneously
every other day. 15 ml peripheral venous EDTA blood was
obtained from each patient before and one month after initiation
of therapy. The samples were always withdrawn prior to the
interferon-b injection. PBMCs were isolated using Ficoll within
one hour after blood withdrawal. Ficoll-isolated PBMCs were then
lysed in RLT buffer (RNeasy kit) and stored at 280uC. Total
RNA was later extracted from each sample using the RNeasy kit.
Afterwards, samples of 7 mg total RNA were processed, labelled,
and hybridized to Affymetrix HG-U133 A and B oligonucleotide
arrays (Affymetrix, Santa Clara, USA). The arrays were scanned
at 3 mm resolution with a Hewlett Packard GeneArray Scanner
G2500A (Affymetrix).
Microarray data pre-processing and analysis
For experimental details and published data regarding the
affymetrix data array please see above (‘‘Gene expression profiling
with microarray analysis’’). The raw Affymetrix microarray data
were pre-processed by applying the MAS5.0 algorithm with a
custom chip definition file (CDF). The custom CDF (http://www.
xlab.unimo.it/GA_CDF/, version 2.1.0) was based on the
information contained in the databases GeneAnnot (version 1.9)
and GeneCards (version 2.41) [13]. Compared to the original
CDF from Affymetrix, the custom CDF defines a set of probe sets,
in which each probe set consists of all specific probes for one
particular gene. This ensures a one-to-one correspondence
between genes and custom probe sets. Data were normalized
separately for the chip types A and B with a loess normalization
using the package affy in the R software environment. Raw and
pre-processed data are publicly available in MIAME format
together with the patients’ clinical data in the Gene Expression
Omnibus (GEO) database (accession number GSE24427). Using
these data we compared PBMC transcript levels of TLR1-10,
MyD88, and MX1 after one month of interferon-b-1b treatment
with pre-treatment levels.
Statistics
For in vitro experiments significance of differences was assessed
by paired t-test or one-way ANOVA with Tukey’s post test.
Differences of protein expression in untreated, interferon-b- or
glatiramer acetate-treated patients were analyzed by Mann
Whitney U test. P-values ,0.05 were considered significant.
Differences of gene expression determined by microarray before
and during interferon-b therapy were analyzed by Wilcoxon
signed-rank test at the a=0.01 significance level.
Results
Interferon-b upregulates TLR3, TLR7, and MyD88 mRNA,
but downregulates TLR6 and TLR9 mRNA in human
mononuclear blood cells
To comprehensively analyze the effects of interferon-b on all
known human TLRs (TLR1-10) and the TLR adaptor molecule
MyD88, PBMCs from healthy donors were stimulated with
1000 U/ml interferon-b for 6 hours. Changes in mRNA expres-
sion levels were subsequently measured by qRT-PCR. The well-
established interferon-b response gene MX1 [14] served as
positive control and was strongly (66.2-fold) induced by interfer-
on-b treatment, proving biological activity of the employed
interferon-b preparation (Fig. 1). Compared to control conditions,
interferon-b caused a significant increase of TLR3 (4.7-fold),
TLR7 (7.4-fold), and MyD88 (2.1-fold) mRNA expression as well
as a significant decrease of TLR6 (2.4-fold) and TLR9 (2.8-fold)
mRNA expression in human PBMCs. While TLR5 mRNA was
not detectable in human PBMCs, TLR1, TLR2, TLR4, TLR8,
and TLR10 mRNA were expressed but not significantly regulated
by interferon-b during the observed time period.
Dose- and time-dependent modulation of TLR expression
in human peripheral blood mononuclear cells by
interferon-b
To further characterize regulation of TLR expression by
interferon-b a kinetic and dose-response study was performed for
the targets significantly modulated by interferon-b as well as for
TLR10. In PBMCs from healthy donors stimulated with 1000 U/
ml interferon-b for 6, 24, and 48 hours the maximal response for
TLR7 and MX1 mRNA was observed between 6 and 24 hours,
while maximum mRNA levels of TLR3 and MyD88 were
detectable after 6 and 24 hours as well as after 24 and 48 hours,
respectively (Fig. 2A). The lowest expression levels of TLR6 and
TLR9 mRNA were observed after 6 and 24 hours and after
Figure 1. Differential regulation of TLR mRNA expression in
human PBMCs by interferon-b. PBMCs from healthy donors were
incubated with 1000 U/ml interferon-b. Untreated cells served as
control. After 6 hours of treatment RNA was isolated and qRT-PCR
performed with primers for TLR1-10, MyD88, and MX1. Results
(mean6SD) from n=3 independent experiments with PBMCs from
different healthy donors are shown as fold-change to unstimulated
controls. The dotted line marks the expression level in unstimulated
control PBMCs, which was set to 1. Statistical significance of differences
was assessed by paired t-test. *p,0.05; **p,0.01; n.d., not detectable.
doi:10.1371/journal.pone.0070626.g001
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6 hours, respectively. The regulatory effects of interferon-b were
still detectable after 48 hours for MyD88 and TLR9 mRNA levels.
Expression of TLR10 after 6, 24, and 48 hours of interferon-b
stimulation was not significantly changed compared to unstimu-
lated conditions. Treatment of PBMCs with various doses of
interferon-b (0, 10, 100, or 1000 U/ml) resulted in a dose-response
effect, with the strongest regulation observed at the highest
concentration of interferon-b (Fig. 2B).
Interferon-b induces TLR7 and MyD88 protein expression
in plasmacytoid dendritic cells
Having established that interferon-b modulates TLR and
MyD88 mRNA expression in PBMCs we were interested to know
which leukocyte subsets are responsible for this effect and whether
the observed changes in mRNA expression are translated into
changes at the protein level. Therefore, we studied regulation of
TLR7 and MyD88 expression by interferon-b in different
leukocyte subsets by flow cytometry. Following incubation of
PBMCs with 1000 U/ml interferon-b for 24 hours, a significant
increase of TLR7 protein was observed specifically in pDCs (MFI
6 SD unstimulated vs. 1000 U/ml interferon-b, 384.76100.0 vs.
894.76159.6), but not in the other leukocyte subsets (monocytes,
mDCs, B cells, CD4+ T cells, CD8+ T cells) investigated (Fig. 3A,
B). Likewise, treatment with interferon-b resulted in a significant
upregulation of MyD88 (443.06131.7 vs. 730.06203.2) exclu-
sively in pDCs. Different technical approaches such as direct
analysis after stimulation or analysis after storage at 280uC for 7
days and subsequent thawing did not result in significantly
different outcomes regarding TLR7 and MyD88 expression in
pDCs in response to interferon-b (Fig. S1).
We also evaluated whether interferon-b treatment affects cell
numbers of different leukocyte subsets in vitro by determining the
percentage of each leukocyte subset among all live cells.
Stimulation of PBMCs with interferon-b for 24 hours significantly
increased the percentage of pDCs in the whole live cell population
(Fig. 3C, D). Except for a slight but significant increase of B cells
and a minor but significant decrease of CD4+ T cells no
quantitative changes were observed in any other leukocyte subset.
Figure 2. Dose- and time-dependent expression of TLR mRNA in PBMCs in response to interferon-b. (A) PBMCs from healthy donors
were incubated with 1000 U/ml interferon-b. Control cells were left untreated. After 6, 24, and 48 hours RNA was isolated and qRT-PCR performed
with primers for the indicated genes. (B) PBMCs were stimulated with 0, 10, 100, or 1000 U/ml interferon-b. After 6 hours (TLR6, TLR9, TLR10) or
24 hours (TLR3, TLR7, MyD88, MX1) RNA was isolated and qRT-PCR analysis performed. Results (mean6SD) from n= 3 independent experiments with
PBMCs from different healthy donors are shown as fold-change to unstimulated controls. Statistical significance was assessed by one-way ANOVA
with Tukey’s post test. IFN-b, interferon-b; *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0070626.g002
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Regulation of TLR mRNA expression in interferon-b-
treated patients with MS in vivo parallels the effects
observed in vitro
To investigate whether regulation of TLRs in vitro is paralleled
by similar changes in interferon-b-treated patients with MS we
analyzed a data set from 25 patients with RRMS before and one
month after start of treatment with interferon-b-1b [10,11] for
gene expression levels of TLR1-10, MyD88, and MX1. Interfer-
on-b therapy was associated with a significant (p,0.01) upregula-
tion of TLR3, TLR7, MyD88, and MX1 mRNA as well as a
significant downregulation of TLR9 mRNA (Fig. 4). Furthermore,
TLR10 mRNA was significantly downregulated in PBMCs of
patients with RRMS after one month of therapy with interferon-b.
In contrast to the observed downregulation of TLR6 mRNA by
interferon-b in PBMCs in vitro, no influence of interferon-b on
TLR6 expression was detected in patients with RRMS in vivo.
Figure 3. Interferon-b upregulates TLR7 and MyD88 protein expression in plasmacytoid dendritic cells in vitro. (A, B, C, D) PBMCs
were either incubated with 1000 U/ml interferon-b or left untreated. (A) After 24 hours cells were stained with antibodies to TLR7 and MyD88 as well
as isotype controls and analyzed by flow cytometry. Mean fluorescence intensity (MFI) was determined. Results are presented as mean6SD (MFITLR7 or
MyD88 – MFIisotype) from n= 3 healthy donors for each cell type and TLR. (B) Representative dot plots and histogram plots of TLR7 and MyD88
expression in pDCs. (C) Percentages of each cell population of all live cells are depicted with each dot representing one healthy donor. (D)
Representative dot plots display the gating strategy for pDCs. Statistical significance was assessed by paired t-test. IFN-b, interferon-b; *p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0070626.g003
IFN-b Modulates TLRs in MS
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Increased expression of TLR7 protein in plasmacytoid
dendritic cells of interferon-b-treated patients with MS
We next investigated whether changes of interferon-b-induced
mRNA expression in PBMCs of patients with MS may also be
detectable at the protein level. Since the in vitro studies had
demonstrated an upregulation of TLR7 and MyD88 protein
expression by interferon-b in pDCs, we determined the expression
levels of these proteins in pDCs of 9 untreated, 7 interferon-b-, and
7 glatiramer acetate-treated patients with a clinically isolated
syndrome (CIS) or RRMS (see Table 1 for patient details) by flow
cytometry. TLR7 expression was significantly (p=0.039) higher in
pDCs of patients treated with interferon-b than in untreated
patients (Fig. 5). Elevated TLR7 expression in pDCs of interferon-
b-treated as compared to glatiramer acetate-treated patients
almost reached statistical significance (p=0.053) as well. A trend
for elevated expression levels under interferon-b treatment was
also observed for MyD88 (p=0.11, untreated vs. interferon-b;
p=0.32, interferon-b vs. glatiramer acetate). Nevertheless, it
should be noted that the mean age in the glatiramer acetate-
treated patient group was higher than in the other two groups
(interferon-b, 30.1 years; glatiramer-acetate, 44.3 years; untreated,
37 years); thus, an impact of age cannot be ruled out at this point.
Pre-treatment with interferon-b leads to enhanced
production of interferon-a upon TLR7 stimulation
Finally, we investigated whether the observed upregulation of
TLR7 in pDCs induced by interferon-b has a functional impact on
the innate immune response, as measured by the production of
cytokines (interferon-a, tumor necrosis factor-a, IL-6, IL-8, IL-10,
IL-23, IL-27) and chemokines (interferon-c-induced protein 10
and macrophage inflammatory protein-1a). To this end, we
induced upregulation of TLR7 by incubating PBMCs of healthy
donors with interferon-b and subsequently stimulated these cells
with the TLR7-specific ligand loxoribine. Analysis by bead-based
immunoassays revealed that the production of interferon-a was
strongly increased in cells pre-treated with interferon-b and
subsequently stimulated with loxoribine (p=0.024; Fig. 6A). A
similar, almost significant (p=0.06), effect was also observed for
tumor necrosis factor-a. In addition, macrophage inflammatory
protein-1a showed a trend for upregulation in loxoribine-treated
cells prestimulated with interferon-b (p=0.11). Expression of the
other cytokines and chemokines analyzed did not appear to be
enhanced by successive stimulation with these two agents.
Treatment with interferon-b or loxoribine alone had no effects
on the release of interferon-a and tumor necrosis factor-a. Using
intracellular flow cytometry, pDCs were identified as the almost
exclusive cellular source of the enhanced release of interferon-a in
Figure 4. Regulation of TLR, MyD88, and MX1 mRNA expression in interferon-b-treated patients with MS. Expression levels of TLR1-10,
MyD88, and MX1 mRNA were determined in PBMCs of 25 patients with RRMS by Affymetrix microarray analysis immediately before and one month
after start of therapy with interferon-b-1b. Boxplots show medians, upper and lower quartiles as well as outliers, and graphically display the spread
(interquartile range) of the pre-processed microarray data. Statistical significance of gene expression changes in response to therapy was assessed by
Wilcoxon signed-rank test. p-values ,0.01 are indicated.
doi:10.1371/journal.pone.0070626.g004
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response to the combined treatment with interferon-b and
loxoribine (Fig. 6B, C).
Discussion
Since interferon-b has genuine antiviral properties [15] and
TLRs play a prominent role in antiviral immunity [6] we
hypothesized that interferon-b may be involved in the regulation
of TLRs, which could be one mechanism underlying the beneficial
effects of interferon-b in MS. Indeed, we herein show that
interferon-b specifically and differentially modulates TLR mRNA
expression in PBMCs of healthy donors and has almost identical
effects on the expression of TLR mRNA in PBMCs of interferon-
b-treated patients with RRMS. In keeping with its antiviral
properties, the TLRs most strongly and consistently regulated by
interferon-b (TLR3, TLR7, and TLR9) contribute to innate
immunity against viruses. Located on the membrane of intracel-
lular vesicles, in particular endolysosomes, these TLRs recognize
viral double-stranded RNA (TLR3), viral single-stranded RNA
(TLR7), or virus- or bacteria-derived DNA (TLR9) [6]. It
therefore seems likely that the observed changes of TLR3,
TLR7, TLR9, and MyD88 mRNA expression are part of the
antiviral defence program induced by interferon-b.
Flow cytometric studies on the effects of interferon-b on TLR
protein expression and on the leukocyte subsets primarily
responding to interferon-b demonstrated that interferon-b upre-
gulates TLR7 and MyD88 protein specifically in pDCs. Again,
these in vitro observations correlated with results obtained in
interferon-b-treated patients with MS whose pDCs displayed a
higher expression level of TLR7 than pDCs of untreated patients.
Since patients treated with glatiramer acetate, an alternative MS
therapeutic, did not exhibit a comparable increase of TLR7 in
pDCs, this effect appears to be specific for interferon-b. While it is
known that interferon-a upregulates TLR7 and MyD88 expres-
sion in naive B cells [16] and that interferon-b increases the
expression of functionally active TLR7 and MyD88 in human
mDCs [17,18], upregulation of TLR7 and MyD88 protein in
pDCs by interferon-b in pDCs of healthy donors in vitro and
increased levels of TLR7 in pDCs of interferon-b-treated patients
in vivo is a novel finding that, to the best of our knowledge, has not
Figure 5. Increased TLR7 and MyD88 protein expression in plasmacytoid dendritic cells of interferon-b-treated patients with MS.
Expression of TLR7 and MyD88 in pDCs of 9 untreated, 7 interferon-b-, and 7 glatiramer acetate-treated patients with CIS/RRMS was analyzed by flow
cytometry. Results are expressed as MFITLR7 or MyD88 – MFIisotype with each dot representing one individual. Empty symbols represent female and filled
symbols male individuals. Statistical significance of differences was assessed by Mann Whitney U test. GA, glatiramer acetate; *p,0.05.
doi:10.1371/journal.pone.0070626.g005
Table 1. Demographic and clinical details of patients shown in Figure 5.
Patients: Treatment
(number of patients)
CIS/RRMS (number of
patients)
Female/Male (number of
patients)
Age (years)
mean ± SD
EDSS median
(range)
Type of interferon-b
treatment (number of
patients)
No treatment (9) 8/1 6/3 37610.6 1 (0–2.5) None
Glatiramer acetate (7) 3/4 4/3 44.3610.4 2 (1–4) None
Interferon-b (7) 5/2 5/2 30.165.6 1.5 (0–3) Interferon-b-1a i.m. (2)
Interferon-b-1a s.c. (3)
Interferon-b-1b s.c. (2)
CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis; EDSS, expanded disability status scale; i.m., intramuscular; s.c., subcutaneous.
doi:10.1371/journal.pone.0070626.t001
IFN-b Modulates TLRs in MS
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e70626
IFN-b Modulates TLRs in MS
PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e70626
been reported before. Of note, since whole populations of PBMCs
were stimulated in our experiments, we cannot discard the
possibility that the interferon-b-induced upregulation of TLR7
and MyD88 in pDCs might be indirect. Further studies with
purified PBMC subsets will be required to analyse the involvement
and exact function of distinct cell populations in this context. Also,
the immune cell populations responsible for regulation of TLR3
and TLR9 expression in response to interferon-b in our
experiments were not identified. TLR9 is known to be expressed
in pDCs and B cells, and TLR3 expression was observed in NK
and T cells as well as in DCs [21–26]. Therefore, these cells might
up- or downregulate the respective receptors in response to
interferon-b. Finally, animal models of MS may aid in the
elucidation of functional aspects of the interaction of interferon-b
and TLRs [19,20].
Although pDCs account for less than 1% of all circulating
mononuclear blood cells (see Fig. 3C), they represent the principal
PBMC subset involved in antiviral innate immunity and are
capable of releasing large amounts of type I interferon in response
to TLR activation [27,28]. We therefore investigated whether
upregulation of TLR7 in pDCs by interferon-b may further
sensitize these cells to the activation of this receptor by its specific
ligands. Indeed, subsequent stimulation of interferon-b-treated
PBMCs with the TLR7 agonist loxoribine resulted in a strongly
enhanced production of interferon-a as well as a less pronounced
increase of tumor necrosis factor-a. Flow cytometry unambigu-
ously confirmed that pDCs were the main cell type responsible for
the increased release of interferon-a following TLR7 activation
after interferon-b pre-treatment. The fact that loxoribine treat-
ment alone did not induce the release of interferon-a from PBMCs
suggests that interferon-b may serve as an important co-factor for
TLR7 activation in human pDCs, which is similar to the
interferon-b-induced sensitization to the TLR7 agonist 3M-001
previously described in human mDCs [18]. Production of
interferon-a by human dendritic cells upon TLR7 ligation
therefore appears to be tightly controlled and to depend on a
further signal, such as interferon-b, in addition to TLR7
stimulation. Altogether, our findings strongly suggest that
upregulation of TLR7 by interferon-b is functionally relevant, as
it is associated with an increased sensitivity towards TLR7
activation, thereby leading to an increased production of specific
cytokines which may result in an amplified innate immune
response. Interestingly, pDCs were reported to accumulate in
white matter lesions and leptomeninges of patients with MS and
numbers of pDCs were increased in the cerebrospinal fluid of
untreated MS patients during relapse [29,30], indicating that
pDCs could on the one hand play a role in MS and on the other
could thus represent a relevant target for interferon-b therapy.
The question arises how these findings may be related to the
beneficial effects, i.e. relapse reduction, by interferon-b in patients
with MS. There is strong and consistent evidence for an increased
risk of MS relapses around the time of viral infections [31,32]. It
therefore seems conceivable that upregulation of TLR7 in pDCs
by interferon-b and a subsequently enhanced antiviral innate
immune response may reduce the risk of virus-triggered MS
relapses. As one example in accordance with this hypothesis, there
is a temporal relationship between infections with influenza A
virus and MS relapses [33], and single-stranded RNA derived
from influenza A virus is a known TLR7 ligand [34]. One could
therefore speculate that an enhanced immune response against
influenza A virus in patients with MS treated with interferon-b
could reduce the risk of influenza A virus-triggered relapses. In
accordance with the concept of an interferon-b-induced enhanced
antiviral state several further genes involved in antiviral detection
and defence mechanisms such as OAS1-3, GBP1, IFIT1, DDX58,
IRF7 and RSAD2 were found to be upregulated after interferon-b
treatment in a former analysis of our array data set [10,35–39].
It was previously shown that interferon-b inhibits TLR9
processing in pDCs, resulting in decreased activation of pDCs
by a TLR9 agonist [40]. The authors of this work proposed that
reduced activation of pDCs by viral pathogens in interferon-b-
treated patients with MS might thus affect the frequency of MS
exacerbations. However, our present data indicate that the
regulation of TLRs by interferon-b involves differential effects
on distinct TLRs including TLR3, TLR7, TLR9, and possibly
TLR10. Furthermore, our results indicate that interferon-b-
induced upregulation of TLR7 is associated with enhanced
activation of pDCs by a TLR7 agonist. The functional
consequences of the interferon-b-induced regulation of different
TLRs may thus differ and have to be taken into account for each
TLR separately.
Increasing evidence suggests that TLRs may also be activated
by host-derived molecules, such as endogenous nucleic acids
bound by autoantibodies, and this phenomenon is thought to play
a crucial role in the development and maintenance of autoimmune
diseases [7]. We have recently demonstrated that endogenous
single-stranded RNA such as miRNA is capable of activating
TLR7 in the CNS, thereby inducing inflammation and neuronal
injury [41]. It is currently unknown whether stimulation of TLRs
by endogenous molecules plays a role in MS, but if this should be
the case, modulation of TLRs by interferon-b may obviously
influence such interactions.
In summary, our work, including both studies on immune cells
from healthy donors and on patients with MS, implicates that
modulation of the innate immune response may be a relevant
mechanism of action of interferon-b in patients with MS and
suggests a role for the innate immune receptor TLR7 as an
important target in this context. We hypothesize that an enhanced
antiviral immune response associated with upregulation of TLR7
in pDCs by interferon-b may reduce the frequency of virus-
triggered MS relapses. Further studies on the functional conse-
quences of the specific and differential regulation of TLRs by
interferon-b may not only shed more light on the regulation of the
Figure 6. Interferon-b pre-treatment leads to strongly increased production of interferon-a upon TLR7 stimulation. (A) PBMCs from
healthy donors were either incubated with 1000 U/ml interferon-b or left untreated for 12 hours. Subsequently, TLR7 was stimulated with 0,1 mM
loxoribine for additional 6 hours. Amounts of cytokines and chemokines were determined in cell culture supernatants by bead-based immunoassays.
Results shown are mean6SD from n=3 healthy donors. For assessment of statistical significance, the values of loxoribine-untreated cells were
subtracted from values of loxoribine-treated cells for both, cells with and without interferon-b pre-treatment, and the resulting differences compared
by paired t-test. * p,0,05. (B, C) Cells were treated as in (A), but brefeldin A was added for the final 3 hours of stimulation before the intracellular
expression of interferon-a was analyzed by flow cytometry. Representative dot plots showing (B) the percentage of CD303+ cells (pDCs) of all
interferon-a positive cells and (C) the percentage of pDCs positive for interferon-a for one donor representative of n= 4. IFN-a, interferon-a; TNF-a,
tumor necrosis factor-a; IFN-b, interferon-b; MIP-1a, macrophage inflammatory protein-1a, IP-10, interferon-c-induced protein 10; IL, interleukin, n.d.,
not detected.
doi:10.1371/journal.pone.0070626.g006
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innate immune response by interferon-b, but possibly also on
pathogenic mechanisms operating in MS.
Supporting Information
Figure S1 Different technical approaches such as direct
analysis after stimulation or analysis after freezing/
thawing do not result in a different outcome regarding
TLR7 and MyD88 expression in pDCs in response to
interferon-b. PBMCs from healthy donors were either incubated
with 1000 U/ml interferon-b or left untreated. After 24 hours cells
were either directly analyzed by flow cytometry or were frozen as
described in the Material and Methods section, stored for 7 days at
280uC, and subsequently thawed and analyzed by flow cytometry.
For flow cytometry PBMCs were stained with antibodies to
identify pDCs, TLR7, and MyD88 as well as isotype controls.
Mean fluorescence intensity (MFI) was determined and fold
change of MFI in interferon-b-treated to untreated was calculated.
Results are presented as mean6SD from n=3 healthy donors for
pDCs. Analysis by paired t-tests showed no significant differences
between directly analyzed and frozen/thawed PBMC.
(DOC)
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